|13 September 2016|


Proclara Biosciences has secured $47 million in funding to support its work in fighting Alzheimer’s, Parkinson’s and other debilitating diseases.

The American biotechnology company – formerly NeuroPhage Pharmaceuticals – is a leader in the development of novel therapies for diseases like these – caused by protein misfolding.

“We are very pleased by the continued support of our investors, which speaks to the strength of our science and the tremendous potential for our therapies to transform the treatment landscape for patients suffering from Alzheimer’s and other neurodegenerative diseases,” said Franz Hefti, Ph.D., president and chief executive officer of Proclara. “Together with our name change, this important corporate milestone marks our continued progress towards bringing to market a new class of medicines to address the urgent needs of patients suffering from debilitating protein misfolding diseases.”